---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-101395"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:11:55.563675+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Director David Lucchino resigns; Katharine Knobil appointed to board

## Summary
- David Lucchino resigned from board effective Aug 26, 2024; no disagreement with management or board.
- Lucchino signed consulting agreement: $9k/quarter through 2026 annual meeting, then $2k/quarter through 2027; option grant (~$150k, capped 8k shares) at 2025 meeting, vesting at 2026 meeting.
- Board reduced size from 7 to 6, then increased to 7 to appoint Katharine Knobil, M.D. as Class III director; also appointed to Compensation Committee.
- Dr. Knobil will serve until 2025 annual meeting; receives standard non-employee director compensation and indemnification.

## SEC filing metadata
- accession: 0000950170-24-101395
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/0000950170-24-101395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/krro-20240826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-101395
- JSON: https://secwatch.observer/filing/0000950170-24-101395.json
- Plain text: https://secwatch.observer/filing/0000950170-24-101395.txt

## Key facts
- Executive change
  David L. Lucchino resigned as Director at Korro Bio, Inc..
  - Action: resigned
  - Role: Director
  source text: On August 26, 2024, David L. Lucchino, a member of our Board of Directors, or the Board, notified us that he resigned from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/0000950170-24-101395-index.htm
- Executive change
  Katharine Knobil, M.D. was appointed as Director at Korro Bio, Inc..
  - Action: appointed
  - Role: Director
  source text: and then increased the number of directors from six to seven to create a vacancy in Class III and then appointed Katharine Knobil, M.D. to fill the newly created vacancy on the Board in Class III effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/0000950170-24-101395-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.